Global Intragastric Balloon Market Report and Forecast 2024-2032

Global Intragastric Balloon Market Outlook

The global intragastric balloon market size reached a value of nearly USD 20.12 million in 2023. The market is expected to grow at a CAGR of 10.60% between 2024 and 2032, reaching a value of about USD 49.83 million by 2032.

Key Trends in the Market

An intragastric balloon refers to a medical device that is placed inside the stomach to lower intragastric space and induce long-lasting weight loss in obese patients. The balloon promotes the feeling of satiation, reduces the stomach’s ability to accommodate food, and serves as a restrictive mechanism to contribute to the weight loss of patients. The use of intragastric balloons, combined with lifestyle interventions and pharmacotherapy, can aid patients to achieve nearly significant body weight loss.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

• Due to sedentary lifestyles and unhealthy food habits, the prevalence of obesity across the globe is surging. The increasing awareness regarding the negative effects of obesity on the quality of life is anticipated to boost the intragastric balloon market demand, as the balloons are intended to boost satiety through neuroendocrine and mechanical mechanisms.

• The ease of placement, general safety, and ease of administration offered by intragastric balloons are driving their deployment. Intragastric balloons offer minimally invasive options for obesity treatment and management, effectively treat obesity-related medical conditions, induce weight loss, and reduce anaesthesia-related and surgical complications while reducing BMI; such benefits are bolstering their preference.

• Increasing research and development (R&D) activities to boost the effectiveness of intragastric balloons while minimising their risk of failure are likely to surge their popularity. The increasing clinical studies to demonstrate the efficacy and safety of innovative balloons and the rising use of the balloon as a bridge treatment for bariatric surgery are further expected to augment the intragastric balloon market development in the forecast period.

• However, several complications are associated with intragastric balloons, including heart attack, oesophageal or gastric perforation, and acute pancreatitis, among others. Issues such as overinflation of the balloon can also be fatal to patients.

Market Analysis

Based on product type, the intragastric balloon market can be segmented into single, dual, and triple. By filling material type, the market is bifurcated into saline filled and gas filled. The major end-users of intragastric balloon include hospitals and ambulatory surgical centres, among others. The regional markets for intragastric balloon can be divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global intragastric balloon market, covering their competitive landscape and latest developments like mergers, acquisitions, investments and expansion plans.

• Apollo Endosurgery, Inc

• Allurion S.a.s.

• ENDALIS

• Easmed

• Accel Medical

• Others

Market Share by Filling Material Type

Saline-filled intragastric balloon posits the properties and features of a thin, extractable, and filling catheter at a valve, hence enabling the removal or addition of saline in situ and customisation of intragastric volume in accordance with the tolerance and desired weight-loss outcomes of the patient. Moreover, research and development activities initiated by the leading companies demonstrate the superiority of saline-filled balloons in effectively bolstering weight loss, which is adding on to their demand.

Meanwhile, a gas-filled intragastric balloon facilitates easy gastric volume titration, and it is swallowed under fluoroscopic visualisation. It is compressed, folded, and fitted into a dissolvable gelatin capsule and can remain implanted for nearly 6 months.

The intragastric balloon market development is bolstered by the increasing approvals of gas-filled and saline-filled intragastric balloons by healthcare bodies like the FDA, which are also approving the use of advanced navigation systems that utilise magnetic resonance for providing a real-time image of the balloon while minimising patients’ and personnel’s exposure to radiation.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Share by Region

North America accounts for a significant share of the market for intragastric balloon owing to the high prevalence of obesity in countries like the United States and the robust healthcare infrastructure in the region. The increasing approvals of innovative intragastric balloons by healthcare bodies such as the FDA and Health Canada are likely to boost the market growth in the forecast period.

The increasing attempt by leading players in the market to enhance the cost-effectiveness of the treatment is anticipated to pose as a significant intragastric balloon market driver. Furthermore, the surging cost-effectiveness of intragastric balloons, the development of biocompatible and technologically advanced intragastric balloons, the rising demand for innovative weight loss treatments, and the high availability of skilled workforce are expected to positively influence the North America market growth in the coming years.

Meanwhile, the Asia Pacific intragastric balloon market is witnessing robust growth owing to the increasing interest towards lowering obesity rates in countries like India and China and the surging approvals and launches of intragastric balloons in the region. For instance, in September 2023, Allurion launched its swallowable gastric balloon capsule, a medical weight-loss device approved by the CDSCO (Central Drugs Standard Control Organisation), in India.

Competitive Landscape

Apollo Endosurgery Inc is a prominent medical technology corporation that is engaged in treating gastrointestinal issues, ranging from interventional obesity treatment to gastrointestinal defect repairs, through minimally invasive surgeries. The company aims to lower overall healthcare costs and reduce complications of surgical procedures through its innovative treatment methods. Based in Texas, its products are marketed and sold in 75 countries across the globe.

Allurion S.a.s. is a company that aims to develop the world’s first full-stack weight-loss platform for eradicating obesity. Through its flagship Allurion Platform, the company enables patients to lose about 10%-15% of their body weight in nearly 16 weeks. The Allurion Balloon is designed to support patients to reduce their food intake and encourage smaller portions at mealtimes, hence training the body to eat less.

ENDALIS is engaged in the development of innovative medical solutions to develop intragastric balloons for patients unable to undergo surgical treatments to reduce obesity. The company actively invests in technological innovations for advancing the development of intragastric balloons that are easy to use and posit no potential risks.

Other major players in the intragastric balloon market include Easmed and Accel Medical, among others.

Key Highlights of the Report